EGFR突变晚期非小细胞肺癌一代EGFR-TKIs耐药后免疫治疗的研究进展  

Research progress of immunotherapy in advanced EGFR mutant non-small cell lung cancer acquired resistance after treated with first-generation EGFR-tyrosine kinase inhibitors

作　　者：石然 周倩 刘利 何敬东[1] SHI Ran;ZHOU Qian;LIU Li;HE Jingdong(Department of Oncology,Huai'an First Hospital Affiliated to Nanjing Medical University,Huai'an 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院肿瘤内科,江苏淮安223300

出　　处：《临床肿瘤学杂志》2021年第8期762-766,共5页Chinese Clinical Oncology

摘　　要：表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)可以显著延长表皮生长因子受体(EGFR)突变非小细胞肺癌(NSCLC)患者的无病进展期,一代EGFR-TKIs研发较早,目前已广泛应用于临床,但治疗后耐药限制了EGFR-TKIs的长期疗效。最近研究发现免疫治疗可为一线EGFR-TKIs耐药的患者提供适度的益处,尤其是T790M突变阴性患者,但其具体作用及机制尚未明确。本文针对免疫治疗对一代EGFR-TKIs耐药患者后续治疗的可行性、治疗方案及疗效预测标志物等方面进行综述。Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)have achieved superior efficacy in patients with EGFR mutation-positive non-small cell lung cancer(NSCLC)in terms of progression-free survival,and first generation EGFR-TKIs have been widely used in clinical practice.However,acquired resistance limits the long-term efficacy of EGFR-TKIs.Recently,studies have proved that immunotherapy could provide moderate benefits for patients acquired resistance after first-line EGFR-TKIs treatment,especially those with negative T790M mutations.Since the specific role and mechanism of immunotherapy are not clear,this article reviews the feasibility,treatment options and markers of efficacy prediction of immunotherapy for patients acquired resistance after first generation EGFR-TKIs.

关 键 词：非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 靶向治疗耐药 免疫治疗 

分 类 号：R735.2[医药卫生—肿瘤]